



Abstract Sulfur [¹⁸F]Fluoride Exchange Reaction Enables Rapid Access to ¹⁸F-Labeled PET Tracers [†]

Austin Craig ¹, Jürgen Kogler ^{1,2}, Fabian Krutzek ^{1,2}, Florian Brandt ^{1,2}, Markus Laube ¹, Martin Ullrich ¹, Cornelius Kurt Donat ¹, Klaus Kopka ^{1,2} and Sven Stadlbauer ^{1,2,*}

- ¹ Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany
- ² Faculty of Chemistry and Food Chemistry, School of Science, TU Dresden, 01069 Dresden, Germany
- Correspondence: s.stadlbauer@hzdr.de
- + Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.

Abstract: Efficient ¹⁸F-fluorination procedures for the production of radiopharmaceuticals are urgently needed to satisfy the increasing demand for clinical diagnostics using positron emission tomography (PET). However, the development of PET tracers is often a time-consuming and challenging process. This work examines the applicability of the recently described sulfur [¹⁸F]fluoride exchange ([¹⁸F]SuFEx) chemistry as a fast screening approach towards a number of clinically relevant PET tracer preparations. The preparation of a number of ¹⁸F-labeled compounds commenced with [¹⁸F]fluoride loading onto a quarternary methylammonium (QMA) cartridge, which was eluted with a methanolic solution containing a base, followed by solvent removal under reduced pressure. Thereafter, the radiolabeling precursors in MeCN were added to the reaction vessels, and allowed to react via [18F]SuFEx at room temperature for 5 min. The radiofluorination reactions were quenched by water dilution followed by C18 cartridge purification. The ¹⁸F-labeled products were isolated by elution from the cartridge with EtOH and the identities of the products were confirmed by radioultra high performance liquid chromatography (UHPLC). The optimized preparations of ¹⁸F-labeled prostate-specific membrane antigen (PSMA) inhibitor, Programmed death-ligand 1 (PD-L1) ligand, cyclooxygenase-2 inhibitor (COXIB), and Fibroblast activation protein alpha inhibitor (FAPI) were achieved with high non-decay corrected isolated activity yields (AY) of 33–57% (n = 12) and >95% radiochemical purity (RCP) in 25 min. The automated radiosynthesis procedures afforded the radiolabeled products in an unoptimized 8–15% AY (n = 5), with >95% RCP in 40 min. The ultra-fast [¹⁸F]SuFEx reaction permitted several structurally diverse ¹⁸F-labeled compounds for potential imaging to be rapidly achieved in excellent isolated AYs and high RCP. Presently, optimization of the automated radiosynthesis and biological assessment of the ¹⁸F-labeled products is underway.

Keywords: fluorine-18; positron emission tomography (PET); 18F-fluorination; [18F]SuFEx; PSMA; FAPI; PD-L1; COX-2 inhibitor

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/ECMC2022-13652/s1.

Author Contributions: Conceptualization, A.C.; methodology, A.C., F.B., M.L., J.K., F.K., C.K.D., and M.U.; resources, K.K. and S.S.; writing—original draft preparation, A.C.; writing—review and editing, M.L., K.K., and S.S.; supervision, S.S.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.



Citation: Craig, A.; Kogler, J.; Krutzek, F.; Brandt, F.; Laube, M.; Ullrich, M.; Donat, C.K.; Kopka, K.; Stadlbauer, S. Sulfur [¹⁸F]Fluoride Exchange Reaction Enables Rapid Access to ¹⁸F-Labeled PET Tracers. *Med. Sci. Forum* **2022**, *14*, 127. https://doi.org/10.3390/ ECMC2022-13652

Academic Editor: Alfredo Berzal-Herranz

Published: 16 November 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

2 of 2

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.